ORXES Therapeutics
We are a leading pharmaceutical group in China focused on the development of novel therapies through original innovation. With a 20-year track record of comprehensive experience in research and development, large-scale production, sales and distribution, we have developed integrated drug development capabilities covering the entire pharmaceutical supply chain.
Building on over a decade of scientific discovery and unwavering commitment, we have established several major technological platforms and are developing potentially revolutionary therapies targeting cardiovascular diseases, including pulmonary hypertension (PH), ischemic stroke, and hypertension, as well as novel treatment for premature ejaculation (PE).
With drug development team with about hundred people, we have conducted rigorous screening of thousands of compounds based on multiple key targets, through which we have developed a robust pipeline of five novel drug programs targeting large patient populations and four main technology platforms. To date, we have established robust patent protection for each of our key novel drug candidates across China, the U.S., the EU, Japan and internationally through PCT.
